DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Hydromet (Hydrocodone Bitartrate / Homatropine Methylbromide) - Summary

 
 



HYDROMET SUMMARY

This product contains hydrocodone (dihydrocodeinone) bitartrate, a semisynthetic centrally acting narcotic antitussive. Homatropine methylbromide is included in a subtherapeutic amount to discourage deliberate overdosage.

HYDROMET (HYDROCODONE/METHYLHOMATROPINE) is indicated for the following:

For the symptomatic relief of cough.


See all Hydromet indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Hydromet (Hydrocodone / Homatropine)

Decision-making tool may help doctors cut unnecessary antibiotic prescribing for children with coughs and respiratory tract infections
Source: Respiratory / Asthma News From Medical News Today [2016.09.02]
Respiratory tract infections (RTI) with cough are the most common reason children are prescribed antibiotics by their doctors, but up to a third of prescriptions may be unnecessary.

Is a Cough Contagious?
Source: MedicineNet Common Cold Specialty [2016.09.02]
Title: Is a Cough Contagious?
Category: Diseases and Conditions
Created: 5/28/2015 12:00:00 AM
Last Editorial Review: 9/2/2016 12:00:00 AM

Whooping Cough (Pertussis) Symptoms, Vaccine Facts
Source: MedicineNet Immunizations Specialty [2016.08.08]
Title: Whooping Cough (Pertussis) Symptoms, Vaccine Facts
Category: Slideshows
Created: 1/27/2010 1:05:00 PM
Last Editorial Review: 8/8/2016 12:00:00 AM

Multi-centre trial to test new treatment for chronic cough
Source: Ear, Nose and Throat News From Medical News Today [2016.06.14]
A clinical trial to test a promising new treatment for chronic cough that could lead to the first new cough drug in 50 years has been launched by the National Institute for Health Research.

Cold and Flu: Finding Relief for Your Cough
Source: MedicineNet benzonatate Specialty [2016.06.07]
Title: Cold and Flu: Finding Relief for Your Cough
Category: Slideshows
Created: 11/16/2012 12:00:00 AM
Last Editorial Review: 6/7/2016 12:00:00 AM

more news >>

Published Studies Related to Hydromet (Hydrocodone / Homatropine)

Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers. [2003.01]
RATIONALE: The subjective, psychomotor, and physiological effects of prescription compounds containing the opioid hydrocodone have not been studied in a population of non-drug-abusing people who might be prescribed these compounds for cough or pain relief. OBJECTIVES: To characterize the effects of a hydrocodone combination product, Hycodan, which contains hydrocodone and a peripherally-acting anticholinergic, homatropine, in non-drug-abusing volunteers... CONCLUSIONS: Hycodan at the highest dose tested had effects similar to that of a prototypic mu agonist, morphine. Both drugs produced pleasant (including drug liking) as well as unpleasant subjective effects. Post-session ratings of overall liking and "want to take drug again" were not significant.

more studies >>

Clinical Trials Related to Hydromet (Hydrocodone / Homatropine)

Single Dose Pharmacokinetics of Egalet´┐Ż Hydrocodone [Completed]

Pharmacokinetic Study of Hydrocodone/APAP in Chronic Pain Patients [Completed]
Objective is to evaluate the pharmacokinetics profile of hydrocodone's metabolite hydromorphone in patients who are taking hydrocodone on a routine basis for more than 3 months for chronic pain and correlate hydromorphone levels to their hydrocodone usage.

Hydrocodone/Acetaminophen for Acute Pain Following Third Molar Tooth Extraction [Completed]
The purpose of this study was to evaluate analgesic efficacy and safety of hydrocodone/acetaminophen compared to placebo in moderate to severe pain following molar extraction.

Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain [Completed]
The primary objective of this study is to evaluate the analgesic efficacy and safety of HYD tablets 20 to 120 mg once-daily dose compared to placebo in subjects with moderate to severe chronic low back pain uncontrolled by their current stable analgesic regimen

Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period. [Completed]
The primary objective of this study is to characterize the long-term safety of Hydrocodone Bitartrate (HYD) tablets 20 to 120 mg once-daily in subjects with chronic nonmalignant and nonneuropathic pain.

more trials >>


Page last updated: 2016-09-02

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015